The Neostigmine Methylsulfate Injection Market Size is valued at USD 156.54 Mn in 2022 and is predicted to reach USD 228.43 Mn by the year 2031 at a 4.4% CAGR during the forecast period for 2023-2031.
Neostigmine methylsulfate is a reversible cholinesterase inhibitor. Cholinesterases are enzymes responsible for breaking down the neurotransmitter acetylcholine at the neuromuscular junction. By inhibiting these enzymes, neostigmine allows acetylcholine to accumulate, leading to increased stimulation of skeletal muscle. A unique stability-indicating reverse phase HPLC method was created and validated for the quantitative determination of associated impurities and degradation impurities in neostigmine methylsulfate API and injectable formulation.
A popular quaternary ammonium chemical called methyl sulphate is utilized as a competitive cholinesterase inhibitor. It raises the levels of acetylcholine by reducing its breakdown in the synaptic cleft. As a non-depolarizing neuromuscular blocking drug, this acetylcholine competes for the binding sites and breaks the neuromuscular blockade. The nicotinic and muscarinic actions are amplified as a result. It makes the skeletal muscles active.
Since neostigmine methylsulfate cannot easily cross the blood-brain barrier, the central nervous system is unaffected. Neostigmine methylsulfate does not absorb well into the digestive system because of its ionic composition. As a result, it is given as a parenteral injection.
Competitive Landscape
Some Major Key Players In The Neostigmine Methylsulfate Injection Market:
- Pfizer Inc.
- Fresenius Kabi AG
- Mylan N.V.
- Sandoz Inc.
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- Hospira (now part of Pfizer)
- Akorn Pharmaceuticals
- Baxter International Inc.
- Hikma Pharmaceuticals
- Endo International
Market Segmentation:
The neostigmine methylsulfate injection market is segmented on the basis of application, distribution channel, and end user. As per application, the market is segmented as myasthenia gravis and reversal of neuromuscular blockade. Acording to distribution channel, the market is divided into hospital, retail pharmacies, and online pharmacies. On the basis of end-users, the market is divided into hospitals, speciality clinics, and ambulatory surgical centres.
Based On Application, The Myasthenia Gravis Segment Is Accounted As A Major Contributor In The Neostigmine Methylsulfate Injection Market.
The myasthenia gravis category is expected to hold a major share of the global neostigmine methylsulfate injection market in 2022. By increasing muscle tone, the cholinesterase inhibitor neostigmine is used to treat the indications of myasthenia gravis. Physostigmine crosses the blood-brain barrier; neostigmine does not. Since there are fewer receptors present in myasthenia gravis, blocking acetylcholinesterase increases the amount of acetylcholine that is available in the synapse and improves its ability to bind to those receptors and cause muscle contraction.
The Hospital Pharmacies Segment Witnessed Development At A Rapid Rate.
The hospital pharmacy is estimated to grow at a rapid rate in the global neostigmine methylsulfate injection market. Increasing hospitalization for treatment of the patients with myasthenia gravis and reversal of neuromuscular blockade. Furthermore, the elderly are more prone to neurological conditions like myasthenia gravis, which frequently need to be treated in hospitals with injections of neostigmine methylsulfate. The need for drugs that treat age-related illnesses, such as neostigmine methylsulfate injections, is rising as the world's elderly population keeps expanding.
In The Region, The North American Neostigmine Methylsulfate Injection Market Holds A Significant Revenue Share.
The North American neostigmine methylsulfate injection market is expected to record the maximum market share in terms of revenue in the near future. Increasing research and development in the region is anticipated to drive the market developments in the coming years. Moreover, rising FDA approvals for various competitors are expected to boost the market growth. A cholinesterase inhibitor called neostigmine methylsulfate injection is recommended for reversing the effects of non-depolarizing neuromuscular blocking drugs (NMBA) after surgery.
Neostigmine Methylsulfate Injection Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 156.54 Mn |
|
Revenue forecast in 2031 |
USD 228.43 Mn |
|
Growth rate CAGR |
CAGR of 4.4% from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By Application, Distribution Channel, End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Pfizer Inc., Fresenius Kabi AG, Mylan N.V., Sandoz Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Hospira (now part of Pfizer), Akorn Pharmaceuticals, and Baxter International Inc. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
